1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Psychological Distress Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Psychological Distress Market, by Disorder Type
8.1.1 Anxiety Disorders
8.1.1.1. Market Revenue and Forecast
8.1.2. Depression
8.1.2.1. Market Revenue and Forecast
8.1.3. Stress-Related Disorders
8.1.3.1. Market Revenue and Forecast
8.1.4. Post-Traumatic Stress Disorder (PTSD)
8.1.4.1. Market Revenue and Forecast
8.1.5. Adjustment Disorders
8.1.5.1. Market Revenue and Forecast
9.1. Psychological Distress Market, by Treatment Type
9.1.1. Pharmacological Treatment
9.1.1.1. Market Revenue and Forecast
9.1.2. Psychotherapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Digital Mental Health Solutions
9.1.3.1. Market Revenue and Forecast
9.1.4. Lifestyle and Wellness Programs
9.1.4.1. Market Revenue and Forecast
10.1. Psychological Distress Market, by Therapy Type
10.1.1. Cognitive Behavioral Therapy (CBT)
10.1.1.1. Market Revenue and Forecast
10.1.2. Counseling and Talk Therapy
10.1.2.1. Market Revenue and Forecast
10.1.3. Mindfulness-Based Therapy
10.1.3.1. Market Revenue and Forecast
10.1.4. Group Therapy
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Disorder Type
11.1.2. Market Revenue and Forecast, by Treatment Type
11.1.3. Market Revenue and Forecast, by Therapy Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Disorder Type
11.1.4.2. Market Revenue and Forecast, by Treatment Type
11.1.4.3. Market Revenue and Forecast, by Therapy Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Disorder Type
11.1.5.2. Market Revenue and Forecast, by Treatment Type
11.1.5.3. Market Revenue and Forecast, by Therapy Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Disorder Type
11.2.2. Market Revenue and Forecast, by Treatment Type
11.2.3. Market Revenue and Forecast, by Therapy Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Disorder Type
11.2.4.2. Market Revenue and Forecast, by Treatment Type
11.2.4.3. Market Revenue and Forecast, by Therapy Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Disorder Type
11.2.5.2. Market Revenue and Forecast, by Treatment Type
11.2.5.3. Market Revenue and Forecast, by Therapy Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Disorder Type
11.2.6.2. Market Revenue and Forecast, by Treatment Type
11.2.6.3. Market Revenue and Forecast, by Therapy Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Disorder Type
11.2.7.2. Market Revenue and Forecast, by Treatment Type
11.2.7.3. Market Revenue and Forecast, by Therapy Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Disorder Type
11.3.2. Market Revenue and Forecast, by Treatment Type
11.3.3. Market Revenue and Forecast, by Therapy Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Disorder Type
11.3.4.2. Market Revenue and Forecast, by Treatment Type
11.3.4.3. Market Revenue and Forecast, by Therapy Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Disorder Type
11.3.5.2. Market Revenue and Forecast, by Treatment Type
11.3.5.3. Market Revenue and Forecast, by Therapy Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Disorder Type
11.3.6.2. Market Revenue and Forecast, by Treatment Type
11.3.6.3. Market Revenue and Forecast, by Therapy Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Disorder Type
11.3.7.2. Market Revenue and Forecast, by Treatment Type
11.3.7.3. Market Revenue and Forecast, by Therapy Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Disorder Type
11.4.2. Market Revenue and Forecast, by Treatment Type
11.4.3. Market Revenue and Forecast, by Therapy Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Disorder Type
11.4.4.2. Market Revenue and Forecast, by Treatment Type
11.4.4.3. Market Revenue and Forecast, by Therapy Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Disorder Type
11.4.5.2. Market Revenue and Forecast, by Treatment Type
11.4.5.3. Market Revenue and Forecast, by Therapy Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Disorder Type
11.4.6.2. Market Revenue and Forecast, by Treatment Type
11.4.6.3. Market Revenue and Forecast, by Therapy Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Disorder Type
11.4.7.2. Market Revenue and Forecast, by Treatment Type
11.4.7.3. Market Revenue and Forecast, by Therapy Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Disorder Type
11.5.2. Market Revenue and Forecast, by Treatment Type
11.5.3. Market Revenue and Forecast, by Therapy Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Disorder Type
11.5.4.2. Market Revenue and Forecast, by Treatment Type
11.5.4.3. Market Revenue and Forecast, by Therapy Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Disorder Type
11.5.5.2. Market Revenue and Forecast, by Treatment Type
11.5.5.3. Market Revenue and Forecast, by Therapy Type
12.1. Acadia Healthcare
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Ascension Seton
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Behavioral Health Network Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. CareTech Holdings PLC
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. North Range Behavioral Health
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Promises Behavioral Health
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pyramid Healthcare
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Strategic Behavioral Health LLC
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sevita (The MENTOR Network)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Universal Health Services Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
